Natural coagulopathy and characteristics of its treatment in COVID-19 patients (Q20-21)

Natural coagulopathy and characteristics of its treatment in COVID-19 patients (Q20-21)

Q20-21_CDM

Overview

Background

Most patients with SARS-CoV-2 (COVID-19) will present with flu-like symptoms (such as fever, myalgia, dry cough, and fatigue). Recently studies have identified multiple abnormalities of coagulation in many COVID-19 patients. The factors associated with the development of thrombosis in patients with COVID-19 have not been fully evaluated and so the understanding of the determinants of thrombotic events in COVID-19 is important to reducing their risk.

Aim

To determine the incidence of arterial and venous thrombotic complications in patients with COVID-19 and subsequent risk of death. Furthermore, the study will evaluate the patient characteristics present prior to COVID-19 diagnosis as risk factors for arterial and venous thrombotic events.

Manuscripts

Presentations

Project Team

Project Co-Lead
Robert W. Platt PhD
Project Co-Lead
Michael Paterson MSc
Project Manager
Co-Site Investigator
Colin R. Dormuth ScD
British Columbia
Co-Site Investigator
Michael Paterson MSc
British Columbia
Analyst
Matthew Dahl BSc
Manitoba
Analyst
Sean Burnett MA, Econ
Manitoba
Analyst
Fangyun Wu MSc
Ontario